Sunday, January 02, 2022 6:48:08 PM
Recent QNTM News
- Quantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM) • IH Market News • 05/18/2026 02:37:38 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 10:00:09 AM
- Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital • GlobeNewswire Inc. • 05/18/2026 07:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2026 11:00:15 AM
- Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026 • GlobeNewswire Inc. • 05/07/2026 11:00:00 AM
- Quantum BioPharma Provides Corporate Update • GlobeNewswire Inc. • 04/27/2026 11:45:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/22/2026 01:31:13 PM
- Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant • GlobeNewswire Inc. • 04/22/2026 01:16:08 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/02/2026 12:30:03 PM
- Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied • GlobeNewswire Inc. • 04/02/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/01/2026 12:02:04 PM
- Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis • GlobeNewswire Inc. • 04/01/2026 12:02:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 11:50:09 AM
- Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis • GlobeNewswire Inc. • 03/30/2026 11:50:00 AM
- Quantum Biopharma Provides Corporate Update • GlobeNewswire Inc. • 03/27/2026 11:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/27/2026 12:10:03 PM
- Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status • GlobeNewswire Inc. • 03/27/2026 12:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/26/2026 12:00:10 PM
- Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis • GlobeNewswire Inc. • 03/26/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/23/2026 12:24:03 PM
- Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd • GlobeNewswire Inc. • 03/23/2026 12:24:00 PM
- Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering • GlobeNewswire Inc. • 03/20/2026 11:35:00 PM
- Quantum BioPharma Provides Corporate Update • GlobeNewswire Inc. • 03/11/2026 11:55:00 PM
- Quantum BioPharma Provides Corporate Update • GlobeNewswire Inc. • 03/10/2026 11:45:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/03/2026 02:19:46 PM
